Monitor the use of proceeds for advancement of product candidates and potential M&A activity. The convertible notes offering closing the next day could impact capital structure and future dilution if converted.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 17 $1.88entry
- T+1 · 7mo ago 0.00%α +0.19% · $1.88
- T+5 · 7mo ago 0.00%α −0.55% · $1.88
- T+20 · 6mo ago 0.00%α −5.37% · $1.88
- T+60 · 4mo ago +377.66%α +371.52% · $8.98
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines raised approximately $1.65 billion through a public offering of 12.15 million common shares at $142.00 per share, alongside a separate $500 million convertible note offering. The proceeds will fund R&D, commercialization of product candidates, and general corporate purposes.
Key Facts
- Company issued 12,147,887 shares of common stock (10,563,381 base + 1,584,506 option) at $142.00 per share
- Net proceeds from equity offering estimated at $1.65 billion after underwriting discounts and expenses
- Concurrent $500 million offering of 0.50% convertible senior notes due 2033
- Proceeds to be used for R&D, potential commercialization of product candidates, general corporate purposes, and potential acquisitions
- Equity offering closed on April 16, 2026; convertible note offering expected to close April 17, 2026
Financial Impact
Raised $1.65 billion from equity offering and $500 million from convertible notes, totaling $2.15 billion in gross proceeds
Risk Factors
- Dilution from issuance of new shares
- Future dilution if convertible notes are converted to equity
- Execution risk in R&D and commercialization efforts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-159289 |
| Document: d95226d8k.htm | 0001193125-26-159289 |
| Document: d95226dex51.htm | 0001193125-26-159289 |
| Document: 0001193125-26-159289-index-headers.html | 0001193125-26-159289 |
| Document: 0001193125-26-159289-index.html | 0001193125-26-159289 |
| Document: 0001193125-26-159289.txt | 0001193125-26-159289 |
Track record
8 reports on RVMDW
0 of 3 bullish or bearish reports moved the stock their way by T+60. Best: 0.00% at T+1 after the Apr 15, 2026 report. 0 of 3 went positive at some point.
Filters
- Apr 17, 202630w ago 8-K Bearish 8/10 Entry $1.88 to $9.07 ▼ −382.45% −375.67% vs SPY
- Apr 16, 202630w ago 8-K Neutral 6/10 Viewing Entry $1.88 to $8.98 ▲ +377.66% +371.52% vs SPY
- Apr 15, 202630w ago 424B5 Neutral 6/10 Entry $1.88 to $8.96 ▲ +376.60% +369.55% vs SPY
- Apr 15, 202630w ago 424B5 Bearish 7/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
- Apr 15, 202630w ago 144 Bearish 6/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
- Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
- Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
- Apr 13, 202631w ago 8-K Bullish 8/10 Entry $1.88 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers